- 1、本文档共72页,可阅读全部内容。
- 2、有哪些信誉好的足球投注网站(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
核医学nuclearmedicinePPT
G L U T PLASMA TISSUE FDG Fluorodeoxyglucose Metabolism [18F]Fluorodeoxyglucose (FDG) PET Control Alzheimer’s Disease Center for Functional Imaging; Life Sciences Division; Lawrence Berkeley National Laboratory; Berkeley, CA. Brain Metabolism ([18F]FDG) [11C]Raclopride PET Brain Study Normal Cocaine Abuser Courtesy BNL PET Project nCi/cc 1000 800 600 400 200 0 Therapeutic Nuclear Medicine Fission products useful in nuclear medicine include: 99Mo, 131I, 133Xe, 137Cs and 90Sr Mo-99 I-131 Differentiated Thyroid Carcinoma 5 mCi Na131I Imaging Treatment Planning 48 h p.i. Differentiated Thyroid Carcinoma Therapy 105 mCi Na131I 27 h p.i. Differentiated Thyroid Carcinoma Post Surgical Resection Therapy 57Co Flood Source + 105 mCi Na131I Differentiated Thyroid Carcinoma 201TlCl and 99mTc-Sestamibi Imaging 4 months after Na131I Therapy Canine Osteosarcoma Tumor distal radius Story of QuadraMetTM -- I 153Sm identified as a useful nuclide for radiotherapy by MU researchers Development began in early 1980’s at MU in collaboration with the Dow Chemical Company [phosphonate ligand complexes;153Sm-EDTMP] Successful in treatment of primary osteosarcoma in canine patients, with added bonus of 18% cure rate [MU College of Veterinary Medicine] One of Our First Patients Bone Scans of Canine Patient Before Treatment: 8/15/85 After Treatment: 3/3/86 Results of Clinical Trial of153Sm-EDTMP in Canine Osteosarcoma Response # of Dogs (%) Survival (months) Disease Free 7 (18%) 11 - 60 Partial Response 25 (62%) 1 - 16 No Response 8 (20%) 0.5 - 1 Story of QuadraMet? -- II Clinical trials began in late 1980’s, with doses supplied by MURR for Phase I studies ~80% efficacy, with ~25% obtaining full pain remission Approved in U.S. for pain palliation of metastatic bone cancer in March, 1997 153Sm-EDTMP [QuadraMet] 99mTc-MDP 153Sm-EDTMP N N PO 3 H 2 PO 3 H 2 PO 3 H 2 PO 3 H 2 153Sm + Experimental Nuclear Medicine Targeting vector (e.g., mAb, peptide hormone, small molecule, etc.) Radio
文档评论(0)